中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 11
Nov.  2023
Turn off MathJax
Article Contents

Exploration and practice of the detoxicating, stasis-resolving, and Yang-warming method in reconstructing immune balance in hepatitis B virus-related liver failure

DOI: 10.3969/j.issn.1001-5256.2023.11.023
Research funding:

National Natural Science Foundation of China(General Program) (82274434);

National Natural Science Foundation of China (81960841);

Guangxi Traditional Chinese Medicine Multidisciplinary Cross Innovation Team Project (GZKJ2306);

The Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guangxi (2019KY0336);

The Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guangxi (2021KY0324)

More Information
  • Corresponding author: MAO Dewen, mdwboshi2005@163.com (ORCID: 0000-0001-9438-9325)
  • Received Date: 2023-03-22
  • Accepted Date: 2023-04-18
  • Published Date: 2023-11-28
  • Liver failure is an acute and critical disease in the field of liver diseases, and liver failure in China is mainly caused by hepatitis B virus (HBV) infection. Professor Mao Dewen has made remarkable achievements in the prevention and treatment of HBV-related liver failure in basic and clinical research by using the detoxicating, stasis-resolving, and Yang-warming method, and in particular, with this method as the technical core, the new clinical prevention and treatment regimen for reconstructing immune balance in HBV-related liver failure lays a foundation for synergistic integrated traditional Chinese and Western medicine therapy for HBV-related liver failure, highlights the therapeutic advantages of traditional Chinese medicine, and makes breakthroughs in the technical and therapeutic bottlenecks of current clinical treatment of HBV-related liver failure, thereby attempting to reduce the incidence and mortality rates of liver failure.

     

  • loading
  • [1]
    NANCHAL R, SUBRAMANIAN R, KARVELLAS CJ, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: Cardiovascular, endocrine, hematologic, pulmonary, and renal considerations[J]. Crit Care Med, 2020, 48( 3): e173- e191. DOI: 10.1097/CCM.0000000000004192.
    [2]
    ZHANG H, JIA L, YAO SW, et al. Value of MELD combined with serum sodium concentration in predicting the short-term outcome of patients with HBV-related acute-on-chronic liver failure in China: A meta-analysis[J]. J Clin Hepatol, 2018, 34( 9): 1950- 1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024.

    张辉, 贾雷, 姚士伟, 等. MELD-Na评分对我国HBV相关慢加急性肝衰竭短期预后预测价值的Meta分析[J]. 临床肝胆病杂志, 2018, 34( 9): 1950- 1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024.
    [3]
    ZHU Y. Professor Wang Chengbai’s experience in treating severe jaundiced liver disease with promoting qi and promoting blood circulation drugs[J]. Chin J Integr Tradit West Med Liver Dis, 2011, 21( 2): 105- 108. DOI: 10.3969/j.issn.1005-0264.2011.02.018.

    朱云. 汪承柏教授重用行气活血药治疗重度黄疸肝病经验[J]. 中西医结合肝病杂志, 2011, 21( 2): 105- 108. DOI: 10.3969/j.issn.1005-0264.2011.02.018.
    [4]
    LI XH. Professor Qian Ying’s considerations and strategies on treatment of chronic severe hepatitis by blocking and reversing therapy[J]. Shanghai J Tradit Chin Med, 2007, 41( 1): 1- 4. DOI: 10.3969/j.issn.1007-1334.2007.01.001.

    李秀惠. 钱英教授“截断逆挽法”治疗慢性重型肝炎的思路与方法[J]. 上海中医药杂志, 2007, 41( 1): 1- 4. DOI: 10.3969/j.issn.1007-1334.2007.01.001.
    [5]
    ZHANG QY, LI XH, QIAN Y, et al. Professor QIAN Ying’s experience on the treatment of chronic severe viral hepatitis[J]. J New Chin Med, 2005, 37( 3): 14- 15. DOI: 10.3969/j.issn.0256-7415.2005.03.005.

    张秋云, 李秀惠, 钱英, 等. 钱英教授治疗慢性病毒性重型肝炎经验介绍[J]. 新中医, 2005, 37( 3): 14- 15. DOI: 10.3969/j.issn.0256-7415.2005.03.005.
    [6]
    CHEN NS, SUN KW. Speedy treatment of serious hepatitis[J]. J New Chin Med, 2001, 33( 1): 3- 4. DOI: 10.3969/j.issn.0256-7415.2001.01.001.

    谌宁生, 孙克伟. 重症肝炎从快速截断论治[J]. 新中医, 2001, 33( 1): 3- 4. DOI: 10.3969/j.issn.0256-7415.2001.01.001.
    [7]
    CHENG HB. Academic discussion on professor ZHOU Zhongying’s thoughts of“Epidemic Toxin”[J]. J Tradit Chin Med, 2021, 62( 7): 564- 567. DOI: 10.13288/j.11-2166/r.2021.07.003.

    程海波. 周仲瑛“疫毒”学术思想探析[J]. 中医杂志, 2021, 62( 7): 564- 567. DOI: 10.13288/j.11-2166/r.2021.07.003.
    [8]
    LYU C, MAO DW, SHI QL, et al. Experience of MAO Dewen treating hepatic failure with the theory of“Toxin-Turbid causing liver failure”[J]. Liaoning J Tradit Chin Med, 2021, 48( 11): 35- 38. DOI: 10.13192/j.issn.1000-1719.2021.11.009.

    吕超, 毛德文, 石清兰, 等. 毛德文“毒邪-毒浊致病”学说治疗肝衰竭经验撷菁[J]. 辽宁中医杂志, 2021, 48( 11): 35- 38. DOI: 10.13192/j.issn.1000-1719.2021.11.009.
    [9]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [10]
    LIU P. Current status of research on the pathogenesis of liver failure[J]. Chin J Pract Intern Med, 2005, 25( 9): 780- 781. DOI: 10.3969/j.issn.1005-2194.2005.09.007.

    刘沛. 肝衰竭发生机制研究现状[J]. 中国实用内科杂志, 2005, 25( 9): 780- 781. DOI: 10.3969/j.issn.1005-2194.2005.09.007.
    [11]
    YE YN, GAO ZL. Three shock hypotheses that my induce liver failure[J]. Infect Dis Info, 2009, 22( 5): 276- 279. DOI: 10.3969/j.issn.1007-8134.2009.05.006.

    叶一农, 高志良. 乙型肝炎肝衰竭发生机制中的三重打击[J]. 传染病信息, 2009, 22( 5): 276- 279. DOI: 10.3969/j.issn.1007-8134.2009.05.006.
    [12]
    XU HQ, LI X, TANG SH. Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 8): 1927- 1930. DOI: 10.3969/j.issn.1001-5256.2022.08.041.

    徐华谦, 李雪, 汤善宏. 炎症反应在慢加急性肝衰竭中的作用及治疗策略[J]. 临床肝胆病杂志, 2022, 38( 8): 1927- 1930. DOI: 10.3969/j.issn.1001-5256.2022.08.041.
    [13]
    DENG TT, LI L, GUAN Y, et al. Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 10): 2346- 2351. DOI: 10.3969/j.issn.1001-5256.2022.10.028.

    邓婷婷, 李莉, 关瀛, 等. 炎性相关标志物判断HBV相关慢加急性肝衰竭预后的研究进展[J]. 临床肝胆病杂志, 2022, 38( 10): 2346- 2351. DOI: 10.3969/j.issn.1001-5256.2022.10.028.
    [14]
    LI XD, XU DP. Immunopathogenesis of acute-on-chronic hepatitis B liver failure[J]. J Prac Hepatol, 2015, 18( 3): 317- 320. DOI: 10.3969/j.issn.1672-5069.2015.02.030.

    李晓东, 徐东平. HBV相关慢加急性肝衰竭免疫病理发病机制研究进展[J]. 实用肝脏病杂志, 2015, 18( 3): 317- 320. DOI: 10.3969/j.issn.1672-5069.2015.02.030.
    [15]
    GWAK GY, KOH KC, KIM HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate[J]. Clin Exp Rheumatol, 2007, 25( 6): 888- 889.
    [16]
    WANG XJ, ZHANG XP, NING Q. Immune-mediated liver failure[J]. J Clin Hepatol, 2014, 30( 10): 984- 991. DOI: 10.3969/j.issn.1001-5256.2014.10.004.

    王晓晶, 张小平, 宁琴. 肝衰竭的免疫发病机制[J]. 临床肝胆病杂志, 2014, 30( 10): 984- 991. DOI: 10.3969/j.issn.1001-5256.2014.10.004.
    [17]
    LI Y, CAI YM. Analysis on composition of syndrome name[J]. China J Chin Med, 2022, 37( 11): 2322- 2325. DOI: 10.16368/j.issn.1674-8999.2022.11.414.

    李奕, 蔡永敏. 证名构成解析[J]. 中医学报, 2022, 37( 11): 2322- 2325. DOI: 10.16368/j.issn.1674-8999.2022.11.414.
    [18]
    HE FJ. Study on constitution of Traditional Chinese Medicine and proteomics on severe exacerbation of chronic hepatitis B[D]. Nanning: Guangxi University of Traditional Chinese Medicine, 2018.

    何发娟. 慢性乙型肝炎重症化倾向期中医体质类型及蛋白质组学的调查研究[D]. 南宁: 广西中医药大学, 2018.
    [19]
    LONG FL, CHEN XM, WANG N, et al. Study on the intervention of detoxicating and stasis-resolving granules on the prognosis of acute-on-chronic liver failure based on the expression Ratio of IL-17 on CD4+T Cells[J]. Lishizhen Med Mater Med Res, 2017, 28( 4): 796- 798. DOI: 10.3969/j.issn.1008-0805.2017.04.010.

    龙富立, 陈小明, 王娜, 等. 基于IL-17在CD4+T细胞表达比例观察解毒化瘀颗粒对慢加急性肝衰竭预后干预的研究[J]. 时珍国医国药, 2017, 28( 4): 796- 798. DOI: 10.3969/j.issn.1008-0805.2017.04.010.
    [20]
    WANG XF, ZHONG YQ, ZHANG RZ, et al. Effect of Wenyang Huazhuo Tuihuang decoction on hepatitis B-related acute-on-chronic liver failure[J]. J Emerg Tradit Chin Med, 2019, 28( 9): 1540- 1542, 1546. DOI: 10.3969/j.issn.1004-745X.2019.09.010.

    王秀峰, 钟云青, 张荣臻, 等. 温阳化浊退黄汤治疗乙肝相关慢加急性肝衰竭的临床研究[J]. 中国中医急症, 2019, 28( 9): 1540- 1542, 1546. DOI: 10.3969/j.issn.1004-745X.2019.09.010.
    [21]
    CHEN YQ, MAO DW, TANG N, et al. Efficacy of modified yinchen sini tang in acute-on-chronic liver failure[J]. Chin J Exp Med Formul, 2015, 21( 18): 163- 166. DOI: 10.13422/j.cnki.syfjx.2015180163.

    陈月桥, 毛德文, 唐农, 等. 茵陈四逆汤加减治疗慢加急性肝衰竭[J]. 中国实验方剂学杂志, 2015, 21( 18): 163- 166. DOI: 10.13422/j.cnki.syfjx.2015180163.
    [22]
    MAO DW, LONG FL, SHENG QS, et al. Clinical study on the treatment of endotoxemia in chronic severe hepatitis with detoxicating and stasis-resolving granules[J]. J Sichuan Tradit Chin Med, 2013, 31( 6): 78- 80.

    毛德文, 龙富立, 盛庆寿, 等. 解毒化瘀颗粒治疗慢性重型肝炎内毒素血症的临床研究[J]. 四川中医, 2013, 31( 6): 78- 80.
    [23]
    WANG MG, MAO DW, ZHANG RZ, et al. Experimental study on the regulation of Cadd45a expression in hepatocytes of acute liver failure rats by detoxicating and stasis-resolving granules[J]. Lishizhen Med Mater Med Res, 2016, 27( 10): 2350- 2352. DOI: 10.3969/j.issn.1008-0805.2016.10.015.

    王明刚, 毛德文, 张荣臻, 等. 解毒化瘀颗粒调控急性肝衰竭大鼠肝细胞Cadd45a表达的实验研究[J]. 时珍国医国药, 2016, 27( 10): 2350- 2352. DOI: 10.3969/j.issn.1008-0805.2016.10.015.
    [24]
    QIN YX, MA YZ, JIANG Q, et al. Protective effect of detoxicating and stasis-resolving granules against D-galactosamine/lipopolysaccharide-induced acute liver failure in rats and its mechanism of action[J]. Hunan J Tradit Chin Med, 2018, 34( 12): 113- 116. DOI: 10.16808/j.cnki.issn1003-7705.2018.12.049.

    覃艳新, 马玉珍, 蒋琴, 等. 解毒化瘀颗粒对D-半乳糖胺/脂多糖诱导急性肝衰竭大鼠的保护作用及机制研究[J]. 湖南中医杂志, 2018, 34( 12): 113- 116. DOI: 10.16808/j.cnki.issn1003-7705.2018.12.049.
    [25]
    CASTILLO-DELA CRUZ P, WANEK AG, KUMAR P, et al. Intestinal IL-17R signaling constrains IL-18-driven liver inflammation by the regulation of microbiome-derived products[J]. Cell Rep, 2019, 29( 8): 2270- 2283.e7. DOI: 10.1016/j.celrep.2019.10.042.
    [26]
    WANG TS, WANG N, ZHANG RZ, et al. Role of immune response and inflammatory injury in the pathogenesis of liver failure[J]. J Clin Hepatol, 2020, 36( 6): 1415- 1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050.

    王挺帅, 王娜, 张荣臻, 等. 免疫反应与炎症损伤在肝衰竭发病机制中的作用[J]. 临床肝胆病杂志, 2020, 36( 6): 1415- 1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Article Metrics

    Article views (100) PDF downloads(10) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return